William Robert Aronson, MD | |
35 Academy St, Laconia, NH 03246-3606 | |
(603) 556-4360 | |
Not Available |
Full Name | William Robert Aronson |
---|---|
Gender | Male |
Speciality | Counselor - Professional |
Location | 35 Academy St, Laconia, New Hampshire |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1962109348 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
103TC1900X | Psychologist - Counseling | (* (Not Available)) | Secondary |
101YP2500X | Counselor - Professional | (* (Not Available)) | Primary |
Mailing Address | Practice Location Address |
---|---|
William Robert Aronson, MD Po Box 6421, Laconia, NH 03247-6421 Ph: (603) 556-4360 | William Robert Aronson, MD 35 Academy St, Laconia, NH 03246-3606 Ph: (603) 556-4360 |
News Archive
Individuals whose insurance covered the cost of a comprehensive medical weight-loss program had one-year outcomes very similar to those of patients who paid for the treatment out of pocket, according to an observational study conducted at Wake Forest Baptist Medical Center.
Sortilin, which is a protein expressed on the surface of nerve cells, plays a crucial role in pain development in laboratory mice - and in all likelihood in humans as well.
Massachusetts General Hospital Cancer Center researchers have discovered a previously unknown feature of common tumor cells - massive overexpression of certain DNA sequences that do not code for proteins.
Dow Jones Newswires/The Wall Street Journal on Severin Schwan, chief executive of Swiss pharmaceutical company Roche Holding AG: "'It is difficult to gauge the impact of the planned U.S. healthcare reform on the pharmaceutical industry,' Schwan told reporters at a media conference to detail 2009 earnings. 'On the one hand, more U.S. citizens will be getting access to healthcare, which is positive. At the same time, pressure on drug prices will certainly increase,' he added." The wire service adds that he also said "decisions on generic biosimilars will be key" (Greil, 2/3).
› Verified 6 days ago